Advanced in Neuroendocrine Tumor

David T. Laidley

St. Joseph's Health Care London, 
London, ON, CA 
Advanced in Neuroendocrine Tumor
St. Joseph's Health Care London, 
London, ON, CA 
OverviewLocationsClinical Research

Overview

David Laidley practices in London, Canada. Mr. Laidley is rated as an Advanced expert by MediFind in the treatment of Neuroendocrine Tumor. His top areas of expertise are Neuroendocrine Tumor, Prostate Cancer, Renal Cell Carcinoma (RCC), and Bone Tumor.

His clinical research consists of co-authoring 23 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 8 articles and participated in 1 clinical trial in the study of Neuroendocrine Tumor.

Gender
Male

Locations

St. Joseph's Health Care London, London, ON, Canada
Other Locations
1151 Richmond St, London, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in mCRPC Patients Who Are 18F-DCFPyL PSMA-avid, Chemotherapy-naïve, and Progressed on Abiraterone (ARROW )
A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in mCRPC Patients Who Are 18F-DCFPyL PSMA-avid, Chemotherapy-naïve, and Progressed on Abiraterone (ARROW )
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: I-131-1095, Enzalutamide
Study Phase: Phase 2
Radioligand fOr locAl raDiorecurrent proStaTe cancER
Radioligand fOr locAl raDiorecurrent proStaTe cancER
Enrollment Status: Completed
Publish Date: September 12, 2025
Intervention Type: Radiation, Drug
Study Drug: 177Lu-PNT2002
Study Phase: Phase 1/Phase 2
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2025
Intervention Type: Drug
Study Drugs: Lutathera, Octreotide
Study Phase: Phase 3
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
An Open Label Phase II, Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours
An Open Label Phase II, Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Other
Study Phase: Phase 2
View 4 Less Clinical Trials

23 Total Publications

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024.
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024.
Journal: Current oncology (Toronto, Ont.)
Published: February 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Laidley's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile